Inozyme Pharma, Inc. (INZY)
| Market Cap | 127.07M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -67.27M |
| Shares Out | 41.80M |
| EPS (ttm) | -2.26 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 837,722 |
| Open | 2.76 |
| Previous Close | 2.76 |
| Day's Range | 2.76 - 3.18 |
| 52-Week Range | 0.99 - 6.25 |
| Beta | 0.79 |
| Analysts | Buy |
| Price Target | 19.46 (+542.24%) |
| Earnings Date | Mar 21, 2023 |
About INZY
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is he... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for INZY stock is "Buy." The 12-month stock price forecast is $19.46, which is an increase of 542.24% from the latest price.
News
Why Earnings Season Could Be Great for Inozyme (INZY)
Inozyme (INZY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Inozyme Pharma to Participate in the Cowen 43rd Annual Health Care Conference
BOSTON, March 01, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mi...
Inozyme Pharma Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701
- Rapid, significant, and sustained increase in plasma pyrophosphate (PPi) observed and encouraging patient reported outcome data in all dose cohorts in ENPP1 Deficiency trial -
Inozyme Pharma to Host Virtual Investor and Analyst Event on Feb. 16, 2023
- Company to share topline data from ongoing Phase 1/2 trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency (PXE) –
Inozyme Pharma Announces Investor and Analyst Event and Highlights 2022 Progress
- Company to share topline data from ongoing Phase 1/2 trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency at virtual event on Thursday, Feb. 16, 2023 –
Inozyme Pharma Announces Peer-Reviewed Publication Revealing Increased Prevalence of ENPP1 Deficiency
- Article in Orphanet Journal of Rare Diseases estimates genetic prevalence of ENPP1 Deficiency at 1 in 64,000 pregnancies, more than tripling prior estimate -
Inozyme Pharma to Participate at the BofA Securities Biotech SMID Cap Conference
BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic min...
Inozyme Pharma Reports Third Quarter 2022 Financial Results and Provides Business Updates
- Topline data from Phase 1/2 clinical trial of INZ-701 in ENPP1 Deficiency on track for the fourth quarter of 2022 –
Inozyme Pharma to Participate in Upcoming Investor Conferences
BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic min...
Inozyme Pharma Announces Publication of Comprehensive ENPP1 Variant Database
- Peer-reviewed article in Human Mutation reports 3-fold increase in pathogenic/likely pathogenic ENPP1 variants –
Inozyme Pharma to Present at H.C. Wainwright 24th Annual Global Investment Conference
BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, t...
Inozyme Pharma Reports Second Quarter 2022 Financial Results and Provides Business Updates
- Recently reported positive preliminary biomarker and safety data from ongoing Phase 1/2 clinical trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency –
Inozyme Pharma Secures Flexible Debt Facility for up to $70 Million with K2 HealthVentures
BOSTON, July 26, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal miner...
Inozyme Pharma Post Encouraging Early Data From Genetic Disorder Trial
Inozyme Pharma Inc (NASDAQ: INZY) has announced preliminary biomarker, safety, and pharmacokinetic (PK) data from the first three subjects in the Phase 1 portion of its ongoing Phase 1/2 trial of INZ-...
Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Subjects with ABCC6 Deficiency (pseudoxanthoma elasticum or PXE)
- Rapid and significant increase in plasma pyrophosphate (PPi) levels observed in all three subjects in lowest dose cohort (0.2 mg/kg) –
How Much Upside is Left in Inozyme Pharma, Inc. (INZY)? Wall Street Analysts Think 309%
The consensus price target hints at a 308.5% upside potential for Inozyme Pharma, Inc. (INZY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earn...
Inozyme Pharma Announces Partnership with Rady Children's Institute for Genomic Medicine to Advance Newborn Screening for Genetic Diseases
New technology aims to expand testing to approximately 1,000 diseases and sequencing to 3.7 million newborns annually New technology aims to expand testing to approximately 1,000 diseases and sequenci...
Inozyme Pharma Appoints Kurt Gunter, M.D., as Chief Medical Officer
BOSTON, June 07, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal miner...
Inozyme Pharma to Present at the 2022 Jefferies Healthcare Conference
BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal miner...
Inozyme Pharma Reports First Quarter 2022 Financial Results and Provides Business Highlights
– Recently reported positive preliminary biomarker and safety data from ongoing Phase 1/2 clinical trial of INZ-701 in ENPP1 Deficiency –
Inozyme Pharma to Present at Upcoming Investor Conferences
BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, tod...
Inozyme Pharma Announces $73 Million Underwritten Offering Priced At-the-Market
BOSTON, April 14, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mine...
Inozyme Pharma Starts Dosing In INZ-701 Trial For Calcification Disorders
Inozyme Pharma Inc (NASDAQ: INZY) has dosed the first patient in its Phase 1/2 trial of INZ-701 in adult patients with ABCC6 Deficiency. Also, the second cohort in the ongoing Phase 1/2 clinical trial...
Inozyme Pharma Provides Update for Phase 1/2 Clinical Trials in ABCC6 Deficiency and ENPP1 Deficiency
- First patient dosed in Phase 1/2 clinical trial in ABCC6 Deficiency –
Inozyme Pharma to Present at the 21st Annual Needham Virtual Healthcare Conference
BOSTON, April 06, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, t...